Results 131 to 140 of about 60,203 (254)

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives

, 2021
Hikmat Abdel-Razeq,1,2 Faris Tamimi,1 Lama Abujamous,3 Sara Edaily,1 Mahmoud Abunasser,1 Rayan Bater,1 Osama Salama1 1Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan; 2Department of Internal Medicine, School of Medicine ...
Tamimi F, Abunasser M, Salama O, Abujamous L, Edaily S, Bater R, Abdel-Razeq H   +6 more
core  

Optimized SPE‐HPLC‐FLD Method for the Simultaneous Determination of Olaparib, Propranolol, and Furosemide in Human Urine

Biomedical Chromatography, Volume 40, Issue 8, August 2026.
ABSTRACT Olaparib belongs to the PARP inhibitors and is widely used as an anticancer drug. Due to frequent side effects, it is usually co‐administered with an antihypertensive, such as propranolol and/or an antidiuretic, such as furosemide. In this study, a highly sensitive HPLC‐FLD method was developed for the simultaneous determination of the three ...
Georgios Kamaris, Antonia Kalagia, Catherine K. Markopoulou   +2 more
wiley   +1 more source

Understanding risk perception and risk‐reducing decision‐making for surgery among individuals with a genetic predisposition to epithelial ovarian cancer

Journal of Genetic Counseling, Volume 35, Issue 4, August 2026.
Abstract Genetic predisposition to hereditary breast and ovarian cancer and Lynch syndrome increases the risk of developing cancer, including epithelial ovarian cancer (EOC). Depending on the pathogenic variant, (e.g., BRCA1 or PMS2) the risk of developing EOC ranges from approximately 3%–60%.
Rebekah Kukurudz‐Gorowski, Sylvia Horn, Pascal Lambert, Kim Serfas, Renée El‐Gabalawy, Alon David Altman, Kirk James McManus, Jessica Nicole Hartley, Mark William Nachtigal   +8 more
wiley   +1 more source

A delayed chemically induced tumorigenesis in Brca2 mutant mice

, 2009
[[abstract]]BRCA2 is a breast cancer susceptibility gene. Germline mutations of BRCA2 account for about 10?30% of familial breast cancer cases. Consistent with its tumor-suppressor activity, BRCA2 plays an important role in DNA repair.
Yan, D.-H.;Wen, Y.;Su, L.-K.;Xia, W.;Wang, S.-C.;Zhang, S.;Gan, L.;Lee, D.-F.;Frey, J. A.;Hortobagyi, G. N.;Mien-Chie Hung
core  

Evaluating the Utility of Paired Tumor and Germline Targeted DNA Sequencing for Pediatric Oncology Patients: A Single Institution Report

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Objective To evaluate the diagnostic yield and utility of universal paired tumor–normal multigene panel sequencing in newly diagnosed pediatric solid and central nervous system (CNS) tumor patients and to compare the detection of germline pathogenic/likely pathogenic variants (PV/LPVs) against established clinical referral criteria for cancer ...
Natalie Waligorski, Rebecca Ronsley, Shannon M. Stasi, Jeffrey Stevens, Erin R. Rudzinski, Christina M. Lockwood, Sarah E. S. Leary, Bonnie L. Cole, Michelle A. Ting, Vera Paulson   +9 more
wiley   +1 more source

A living biobank of sarcoma patient‐derived cell cultures reveals multi‐omic and functional insights that capture disease heterogeneity

Clinical and Translational Medicine, Volume 16, Issue 7, July 2026.
Preclinical models for sarcoma that preserve tumour biology are urgently needed to advance mechanistic understanding and functional precision oncology. 29 early‐passage patient‐derived sarcoma cell (PDC) cultures from 19 patients, representing 11 sarcoma subtypes were established and extensively characterized.
Stefanie Gijsels, Suzanne Fischer, David Creytens, Sándor Dedeyne, Felix De Vuyst, Cláudio Pinheiro, Fleur Cordier, Sarah‐Lee Bekaert, Nadine Van Roy, Kaat Durinck, Jarne Pauwels, Kris Gevaert, Pieter Mestdagh, Jo Vandesompele, Pekka Rappu, Jyrki Heino, An Hendrix, Gabrielle H. van Ramshorst, Gwen Sys, Olivier De Wever   +19 more
wiley   +1 more source

Preventing hereditary cancers caused by opportunistic carcinogens

, 2011
Objectives Previous studies reported inherited BRCA1/2 deficits appear to cause cancer by impairing normal protective responses to some carcinogens.
Bernard Friedenson
core   +1 more source

Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy

MedComm, Volume 7, Issue 7, July 2026.
Tumor progression is driven by heterogeneity occurring across multiple biological scales. At the molecular level, tumor cells exhibit alterations across distinct omics layers, including genomic mutations, epigenomic reprogramming, transcriptional changes, and proteomic remodeling, collectively shaping tumor cell phenotypes and functional states.
Hanwen Hu, Zhixing Hao, Lili Li, Huiying Liu, Chenghui Yang, Zhen Wang   +5 more
wiley   +1 more source

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical Development

The World Journal of Men's Health
Prostate cancer (PC) treatment has reached a milestone with the introduction of poly(ADP-ribose) polymerase (PARP) inhibitors. PARP inhibitors (PARPi) induce breaks in single-stranded and/or double-stranded DNA, resulting in synthetic lethality in ...
Whi-An Kwon
doaj   +1 more source